Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Abstract

Abstract. The aim of the present study was to investigate the usefulness of serum anti-p53 antibody (Ap53Ab) measurement for the diagnosis of colorectal cancer (CRC), and the clinical significance of the association between Ap53Ab expression and survival rate. Ap53Ab, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 were measured by ELISA in 674 CRC patients and 115 healthy volunteers (control group). The half-life time of Ap53Ab and CEA was calculated. The association between positive Ap53Ab expression and clinicopathological characteristics, including survival rate, was analyzed. Of the 674 CRC patients, 195 (28.9%) were positive for Ap53Ab expression, while the positive rates of CEA and CA19-9 level were 39.9 and 16.9%, respectively. Positivity for Ap53Ab alone was observed in 94 patients (13.9%), whereas the positivity rate of any markers examined was 58.7%. The mean half-life of Ap53Ab and CEA was 30.7 and 11.3 days, respectively. Positive expression of Ap53Ab was significantly associated with the depth of tumor invasion (P<0.001), lymph node metastasis (P=0.024), stage (P<0.001) and CEA level (P= 0.005). No significant correlation between Ap53Ab expression and poor survival rate was observed. The positive rate of Ap53Ab was higher compared with that of CEA and CA19-9 in early-stage CRC. The combination of these markers improved the diagnostic yield of CRC up to ~60%. Furthermore, Ap53Ab expression was associated with lymph node metastasis, but not with shorter survival. These results indicated that the measurement of Ap53Ab may contribute to increased rate of detection of CRC, particularly in patients with early-stage disease, in clinical practice.

A case of stercoral colitis with marked elevation of serum carcinoembryonic antigen

“…Unfortunately, there are no data on reactivity with NFAs. While the half‐life of CEA in blood is reported to be 4‐12 days, the rate of decrease in serum CEA levels in our case was clearly faster than that. Although the half‐life times of NFAs are unknown, this finding suggests the possibility of the involvement of NFAs in serum CEA elevation if the EIA kits show cross‐reactivity with NFAs.…”

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

“…In addition, the reference lists of review articles and related articles were manually screened to identify additional studies. Finally, a total of 80 articles involving 145 specific tumour‐associated autoantibodies detected in patients with CRC were selected (Table ) . Anti‐p53 antibody was the most commonly studied autoantibody, followed by MUC1, CEA, c‐myc, survivin, HDAC5, p62, ANXA4, koc, NY‐CO‐16, NY‐ESO‐1, RPH3AL, cyclin B, Imp1, IMPDH2 and MAGEA3.…”

“…Therefore, in order to further explore the potential diagnostic efficacy of autoantibodies, we performed a meta‐analysis of studies that assessed the diagnostic relevance of p53 autoantibody for CRC. After exclusion of 14 studies in which the blood samples were not collected before initiation of treatment (Table ), 27 studies published in 24 articles mentioning anti‐p53 were included in the meta‐analysis (Table ).…”

Uselessness of Serum p53 Antibody for Detecting Colitis-associated Cancer in the Era of Immunosuppressive Therapy

“…The value in each sample was determined by comparing the optical density of the sample to that of the anti-p53 standard. The cut-off value was 1.3 U/ml, according to a previous colorectal cancer study (11,14). The carcinoembryonic antigen (CEA) levels were measured using a CEA-2 enzyme immune assay (EIA) kit (Elecsys CEAII; Roche Diagnostics K.K., Tokyo, Japan), following the manufacturer's instructions with a cut-off value of 5.0 ng/ml.…”

“…The usefulness of measuring serum anti-p53 Antibodies (Abs) in various malignant tumors has been suggested (6)(7)(8)(9). Compared to conventional tumor markers, anti-p53 Abs is useful for detecting early colorectal cancer (10)(11)(12). Yoshizawa et al reported the usefulness of measuring serum anti-p53 Abs in CAC in 2007 (13), which constituted this assessment eligible for health insurance coverage in Japan during that same year.…”